Combining anticancer drugs with osteoprotective agents in prostate cancer —A contemporary update

Treatment of metastatic hormone-sensitive (mHSPC) and castration-resistant prostate cancer (mCRPC) is a multimodal and interdisciplinary process that frequently affects an elderly and frail population. In these patients, changes in bone metabolism can imply a significant impact on all-cause morbidity as well as cancer-related outcomes. Uniquely, these changes can rely on metastatic bone disease itself, but also on treatment-related changes in bone mineral density that are inherent to long-term androgen deprivation therapy (ADT).
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Tags: Review article Source Type: research